Healthy Skepticism Library item: 6609

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Lexchin J, Vitry A.
Re: the promotion of Lincocin (lincomycin) and Dalacin C (clindamycin)
1995 Nov;

Abstract:

In the Philippines the subsidiary of Upjohn is marketing Lincocin (lincomycin) and Dalacin C (clindamycin) for use in upper respiratory tract infections. According to the scientific literature safety concerns with these two drugs mean that they are not first choices for these conditions.

Keywords:
*analysis/Philippines/developing countries/Lincocin/Dalacin C/antibiotics/Upjohn/safety & risk information/quality of information/MaLAM/Medical Lobby for Appropriate Marketing/EVALUATION OF PROMOTION: DRUG SAFETY/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPING COUNTRIES/PROMOTION IN SPECIFIC THERAPEUTIC AREAS: ANTIBIOTICS